Market Cap 10.01M
Revenue (ttm) 1.18M
Net Income (ttm) -1.18M
EPS (ttm) N/A
PE Ratio 0.00
Forward PE N/A
Profit Margin -100.00%
Debt to Equity Ratio 0.38
Volume 43,100
Avg Vol 14,632
Day's Range N/A - N/A
Shares Out 4.35M
Stochastic %K 6%
Beta 1.31
Analysts Strong Sell
Price Target $20.33

Company Profile

BioLineRx Ltd., a commercial stage biopharmaceutical company, develops and commercializes therapeutics for oncology and rare diseases. The company's pipeline includes APHEXDA (motixafortide), a peptide that is in Phase 1 clinical trial for the treatment of sickle cell disease, and Phase 2b clinical trial for the treatment of pancreatic cancer, as well as completed Phase 3 clinical trial for the treatment of multiple myeloma. It develops BL-5010, a pen-like applicator containing an acidic aqueous...

Industry: Biotechnology
Sector: Healthcare
Phone: 972 8 642 9100
Fax: 972 8 642 9101
Address:
Modi’in Technology Park, 2 HaMa’ayan Street, Hevel Modi'in, Israel
gargoyl
gargoyl Apr. 1 at 3:12 PM
$BLRX 👀 about to explode MM book split open , can’t dark pool this story anymore, watch and learn Beast 🦍 mode inevitable Long the 🦋 🎯 $18.99
0 · Reply
gargoyl
gargoyl Apr. 1 at 3:07 PM
$BLRX 👀 BiolineRx playing with big boyz … 🎯 $18.99 $MRK $AZN
0 · Reply
gargoyl
gargoyl Apr. 1 at 3:01 PM
$BLRX 👀 Value and Growth Target 🎯 $18.99 $XBI $REGN $PFE
0 · Reply
TwongStocks
TwongStocks Mar. 27 at 8:15 PM
$BLRX As mentioned a month ago, the SEC is finally requiring insiders at foreign issuers like BLRX to report insider transactions. Phil Serlin's Form 3 was filed today, which reports his current shares and options. When he makes trades, he will make Form 4 filings. https://www.sec.gov/Archives/edgar/data/1493277/000117891326001790/xslF345X06/zk2634968.xml The Form 3 reports the number of ordinary shares. For those who trade the ADS on NASDAQ, 1 ADS = 600 ordinary shares. Phil owns: • 5,131,800 ordinary shares (equivalent to 8,553 ADS) • 14,218,800 options at prices ranging from $0.045 to $0.287. In terms of ADS, that's the equivalent of 23,698 options at prices ranging from $27 to $172.20.
0 · Reply
tankwfwf
tankwfwf Mar. 26 at 10:04 PM
$BLRX probably about the time Phil makes an offering that will fuck the shares that are ADR's. Just watch the way he does an ER and then a few days latter announces something that he could have announced at the ER. He is just polishing a turd..
0 · Reply
Biotechs5454
Biotechs5454 Mar. 26 at 2:02 PM
$BLRX Anyone know offhand when the next ADR fee will be charged? TIA
0 · Reply
ABDeb
ABDeb Mar. 26 at 1:54 PM
0 · Reply
TwongStocks
TwongStocks Mar. 26 at 11:18 AM
$BLRX BioLineRx Announces Initiation of Phase 1/2a Study of GLIX1 for the Treatment of Glioblastoma (GBM) https://www.prnewswire.com/news-releases/biolinerx-announces-initiation-of-phase-12a-study-of-glix1-for-the-treatment-of-glioblastoma-gbm-302725980.html The Phase 1 part of the trial is expected to recruit up to 30 patients with recurrent and progressive GBM and other high-grade glioma. The objective is to establish a maximum tolerated dose (MTD) and/or a recommended dose based on safety, PK/PD and preliminary efficacy. Data from the Phase 1 part of the trial are anticipated in H1 2027.
0 · Reply
DARKP00L
DARKP00L Mar. 26 at 11:17 AM
$BLRX 07:17 on Mar. 26 2026 BioLineRx Launches First Human Trial For Brain Cancer Drug #tradeideas
0 · Reply
ZacksSCR
ZacksSCR Mar. 23 at 9:12 PM
$BLRX: Full Year 2025 Results https://buff.ly/AcclCWk
0 · Reply
Latest News on BLRX
Earnings Scheduled For March 23, 2026

2026-03-23T11:11:27.000Z - 10 days ago

Earnings Scheduled For March 23, 2026


BioLineRx Reports 2025 Financial Results and Provides Corporate Update

Mon, 23 Mar 2026 07:00:00 -0400 - 10 days ago

BioLineRx Reports 2025 Financial Results and Provides Corporate Update


BioLineRx (BLRX) and Others Set to Announce Earnings

2026-03-23T00:55:17.000Z - 10 days ago

BioLineRx (BLRX) and Others Set to Announce Earnings


BioLineRx to Report 2025 Annual Results on March 23, 2026

Mon, 16 Mar 2026 07:00:00 -0400 - 17 days ago

BioLineRx to Report 2025 Annual Results on March 23, 2026


BioLineRx (BLRX) Q3 Revenue Declines Amid New Joint Venture

2025-11-24T12:34:08.000Z - 4 months ago

BioLineRx (BLRX) Q3 Revenue Declines Amid New Joint Venture


Earnings Scheduled For November 24, 2025

2025-11-24T11:11:10.000Z - 4 months ago

Earnings Scheduled For November 24, 2025


BioLine Rx's Earnings: A Preview

2025-11-21T15:01:37.000Z - 4 months ago

BioLine Rx's Earnings: A Preview


BioLineRx to Report Third Quarter 2025 Results on November 24, 2025

Tue, 18 Nov 2025 07:00:00 -0500 - 4 months ago

BioLineRx to Report Third Quarter 2025 Results on November 24, 2025


Earnings Scheduled For August 14, 2025

2025-08-14T08:32:32.000Z - 8 months ago

Earnings Scheduled For August 14, 2025


BioLineRx to Report Second Quarter 2025 Results on August 14, 2025

Thu, 07 Aug 2025 07:00:00 -0400 - 8 months ago

BioLineRx to Report Second Quarter 2025 Results on August 14, 2025


Why Is Nano-Cap BioLineRx Stock Surging On Friday?

Fri, 30 May 2025 13:58:03 -0400 - 10 months ago

Why Is Nano-Cap BioLineRx Stock Surging On Friday?


Earnings Scheduled For May 27, 2025

2025-05-27T08:32:09.000Z - 11 months ago

Earnings Scheduled For May 27, 2025


A Look at BioLine Rx's Upcoming Earnings Report

2025-05-26T14:01:50.000Z - 11 months ago

A Look at BioLine Rx's Upcoming Earnings Report


BioLineRx to Report First Quarter 2025 Results on May 27, 2025

Tue, 20 May 2025 07:00:00 -0400 - 11 months ago

BioLineRx to Report First Quarter 2025 Results on May 27, 2025


BioLineRx Reports 2024 Financial Results and Provides Corporate Update

Mon, 31 Mar 2025 07:00:00 -0400 - 1 year ago

BioLineRx Reports 2024 Financial Results and Provides Corporate Update


Uncovering Potential: BioLine Rx's Earnings Preview

2025-03-28T16:01:40.000Z - 1 year ago

Uncovering Potential: BioLine Rx's Earnings Preview


BioLineRx to Report 2024 Annual Results on March 31, 2025

Mon, 24 Mar 2025 07:00:00 -0400 - 1 year ago

BioLineRx to Report 2024 Annual Results on March 31, 2025


BioLineRx Issues Letter to Shareholders

Tue, 21 Jan 2025 07:00:00 -0500 - 1 year ago

BioLineRx Issues Letter to Shareholders


Nasdaq Surges Over 200 Points; BioLineRx Shares Plummet

2025-01-06T19:01:37.000Z - 1 year ago

Nasdaq Surges Over 200 Points; BioLineRx Shares Plummet


BioLineRx Announces $10 Million Registered Direct Offering

Mon, 06 Jan 2025 08:57:00 -0500 - 1 year ago

BioLineRx Announces $10 Million Registered Direct Offering


Earnings Scheduled For November 25, 2024

2024-11-25T08:32:08.000Z - 1 year ago

Earnings Scheduled For November 25, 2024


BioLineRx to Report First Quarter 2024 Results on May 28, 2024

May 22, 2024, 7:00 AM EDT - 2 years ago

BioLineRx to Report First Quarter 2024 Results on May 28, 2024


BioLineRx Announces $6 Million Registered Direct Offering

Apr 1, 2024, 9:00 AM EDT - 2 years ago

BioLineRx Announces $6 Million Registered Direct Offering


gargoyl
gargoyl Apr. 1 at 3:12 PM
$BLRX 👀 about to explode MM book split open , can’t dark pool this story anymore, watch and learn Beast 🦍 mode inevitable Long the 🦋 🎯 $18.99
0 · Reply
gargoyl
gargoyl Apr. 1 at 3:07 PM
$BLRX 👀 BiolineRx playing with big boyz … 🎯 $18.99 $MRK $AZN
0 · Reply
gargoyl
gargoyl Apr. 1 at 3:01 PM
$BLRX 👀 Value and Growth Target 🎯 $18.99 $XBI $REGN $PFE
0 · Reply
TwongStocks
TwongStocks Mar. 27 at 8:15 PM
$BLRX As mentioned a month ago, the SEC is finally requiring insiders at foreign issuers like BLRX to report insider transactions. Phil Serlin's Form 3 was filed today, which reports his current shares and options. When he makes trades, he will make Form 4 filings. https://www.sec.gov/Archives/edgar/data/1493277/000117891326001790/xslF345X06/zk2634968.xml The Form 3 reports the number of ordinary shares. For those who trade the ADS on NASDAQ, 1 ADS = 600 ordinary shares. Phil owns: • 5,131,800 ordinary shares (equivalent to 8,553 ADS) • 14,218,800 options at prices ranging from $0.045 to $0.287. In terms of ADS, that's the equivalent of 23,698 options at prices ranging from $27 to $172.20.
0 · Reply
tankwfwf
tankwfwf Mar. 26 at 10:04 PM
$BLRX probably about the time Phil makes an offering that will fuck the shares that are ADR's. Just watch the way he does an ER and then a few days latter announces something that he could have announced at the ER. He is just polishing a turd..
0 · Reply
Biotechs5454
Biotechs5454 Mar. 26 at 2:02 PM
$BLRX Anyone know offhand when the next ADR fee will be charged? TIA
0 · Reply
ABDeb
ABDeb Mar. 26 at 1:54 PM
0 · Reply
TwongStocks
TwongStocks Mar. 26 at 11:18 AM
$BLRX BioLineRx Announces Initiation of Phase 1/2a Study of GLIX1 for the Treatment of Glioblastoma (GBM) https://www.prnewswire.com/news-releases/biolinerx-announces-initiation-of-phase-12a-study-of-glix1-for-the-treatment-of-glioblastoma-gbm-302725980.html The Phase 1 part of the trial is expected to recruit up to 30 patients with recurrent and progressive GBM and other high-grade glioma. The objective is to establish a maximum tolerated dose (MTD) and/or a recommended dose based on safety, PK/PD and preliminary efficacy. Data from the Phase 1 part of the trial are anticipated in H1 2027.
0 · Reply
DARKP00L
DARKP00L Mar. 26 at 11:17 AM
$BLRX 07:17 on Mar. 26 2026 BioLineRx Launches First Human Trial For Brain Cancer Drug #tradeideas
0 · Reply
ZacksSCR
ZacksSCR Mar. 23 at 9:12 PM
$BLRX: Full Year 2025 Results https://buff.ly/AcclCWk
0 · Reply
frontiere
frontiere Mar. 23 at 3:30 PM
$BLRX BioLineRX ref=$2.45 - thanks to @TwongStocks for this helpful highlight of 20-F not in earnings PR Long a mid size pstn
0 · Reply
OpenOutcrier
OpenOutcrier Mar. 23 at 11:45 AM
$BLRX (-2.3% pre) BioLineRx Reports 2025 Financial Results and Provides Corporate Update https://ooc.bz/l/96882
0 · Reply
TwongStocks
TwongStocks Mar. 23 at 11:39 AM
$BLRX 20-F filing https://www.sec.gov/ix?doc=/Archives/edgar/data/1498403/000117891326001581/zk2634707.htm Some items not mentioned in this morning's PR: • Confirmed that Gloria initiated APHEXDA's SCM bridging study in China in Nov 2025, with 1st patient in Dec. Data expected 18 months after initiation (approx mid-2027). • Confirmed that Gloria has not advanced the Phase 2b PDAC trial in China testing APHEXDA with zimberelimab. Was originally planned for initiation in 1H 2025, currently delayed. • No mention in the 20-F whether the $6.7M in sales for 2025 was enough to trigger a milestone payment from Ayrmid.
0 · Reply
StocktwitsEarnings
StocktwitsEarnings Mar. 23 at 11:21 AM
$BLRX Q4 '25 Earnings Results & Recap • Reported GAAP EPS of -$0.51 up 91.50% YoY • Reported revenue of $0.19M down -98.35% YoY • BioLineRx expects to continue incurring significant expenses and net losses for the foreseeable future due to planned development activities for GLIX1 and motixafortide, with current cash sufficient into the first half of 2027.
0 · Reply
TwongStocks
TwongStocks Mar. 23 at 11:18 AM
$BLRX APHEXDA 2025 royalty revenue by quarter: Q1: $255K from $1.4M in sales by Ayrmid Q2: $304K from $1.7M in sales by Ayrmid Q3: $427K from $2.4M in sales by Ayrmid Q4: $194K from $1.2M in sales by Ayrmid BLRX received $1.18M in total royalty revenue during 2025, from $6.7M in sales by Ayrmid. Big dip in Q4 net sales by Ayrmid, which reduced BLRX's Q4 royalty.
0 · Reply
Zkoko_Bio
Zkoko_Bio Mar. 23 at 11:09 AM
$BLRX This was "ze shit" back in the days with tons of BO rumors! Not sure what happened to it since...
1 · Reply
TwongStocks
TwongStocks Mar. 23 at 11:06 AM
$BLRX Reports 2025 Financial Results and Provides Corporate Update https://ir.biolinerx.com/news-releases/news-release-details/biolinerx-reports-2025-financial-results-and-provides-corporate • On track to initiate Phase 1/2a clinical trial of GLIX1 for treatment of glioblastoma (GBM) by end of this month. Data from the Phase 1 part of the trial are anticipated in H1 2027. • $20.9M cash as of Dec 31, runway into 1H 2027 • CheMo4METPANC Phase 2b prespecified interim/futility analysis is planned when 40% of progression-free survival (PFS) events are observed, expected in 2026. • For the full-year 2025, APHEXDA sales were $6.7 million, which provided royalty revenue to the Company of $1.18 million.
0 · Reply
RunningSam
RunningSam Mar. 23 at 11:05 AM
$BLRX BioLineRx GAAP EPS of $0.00 beats by $0.68, revenue of $1.18M misses by $0.3M
0 · Reply
dennilly23
dennilly23 Mar. 17 at 4:29 PM
$BLRX Not sure what to expect besides the clinical trials.
1 · Reply
TwongStocks
TwongStocks Mar. 16 at 11:01 AM
$BLRX ER scheduled March 23. Conference call at 8:30am ET. https://ir.biolinerx.com/news-releases/news-release-details/biolinerx-report-2025-annual-results-march-23-2026
0 · Reply
BLRXlongRIPorYOLO
BLRXlongRIPorYOLO Mar. 12 at 7:01 PM
$BLRX hi. Been a while. Anyone got a quick synopsis of wtf happening here 😂
1 · Reply
TwongStocks
TwongStocks Mar. 12 at 5:42 PM
$BLRX The GLIX1 Phase 1 trial has posted on the clinicaltrials website https://clinicaltrials.gov/study/NCT07464925 A Phase 1 Safety and Dose Finding Study of GLIX1 in Adults With Recurrent or Progressive High-grade Glioma Status: Not yet Recruiting Estimated Start: March 2026 Estimated Enrollment: 30 Primary completion: June 2027 Study Completion: Dec 2027 Primary endpoints are Safety Profile (TEAEs) and Maximum Tolerated Dose.
0 · Reply